Candidiasis in the transplant patient.
The widely accepted practice of empirically administering amphotericin B to immunocompromised patients with fever unresponsive to antibiotics poses a hazard to transplant recipients receiving immunosuppression with cyclosporine. Improved methods of Candida detection and less toxic antifungals are urgently needed, but in the interim, treatment regimens should require a greater index of suspicion before initiating amphotericin therapy in patients receiving cyclosporine.
D000666:Amphotericin B / Q000627:therapeutic use; D001424:Bacterial Infections / Q000517:prevention & control; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology*; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use; D006084:Graft Rejection; D006098:Granulocytes / Q000637:transplantation; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D011188:Potassium / Q000627:therapeutic use; D014181:Transplantation Immunology; D014861:Washington
D003524:Cyclosporins; D000666:Amphotericin B; D011188:Potassium